DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “hold” rating reiterated by research analysts at Northland Securities in a note issued to investors on Thursday, November 2nd. They presently have a $50.00 price objective on the medical device company’s stock. Northland Securities’ price objective points to a potential downside of 9.27% from the company’s current price.
Other analysts have also issued research reports about the company. BMO Capital Markets reiterated an “outperform” rating and issued a $62.00 price target (down previously from $90.00) on shares of DexCom in a report on Thursday, September 28th. Raymond James Financial, Inc. downgraded DexCom from an “outperform” rating to a “mkt perform” rating in a research report on Friday, September 29th. Canaccord Genuity reissued a “buy” rating and set a $69.00 price objective (down from $90.00) on shares of DexCom in a report on Thursday, September 28th. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a report on Wednesday, October 25th. Finally, Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. DexCom currently has an average rating of “Buy” and a consensus target price of $70.69.
DexCom (DXCM) opened at $55.11 on Thursday. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.
In other news, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $44.82, for a total value of $73,280.70. Following the sale, the executive vice president now owns 65,049 shares of the company’s stock, valued at $2,915,496.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $72.27, for a total transaction of $234,443.88. The disclosure for this sale can be found here. Insiders have sold a total of 27,329 shares of company stock worth $1,648,729 over the last quarter. 1.70% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the company. DF Dent & Co. Inc. raised its position in shares of DexCom by 438.2% in the third quarter. DF Dent & Co. Inc. now owns 75,856 shares of the medical device company’s stock valued at $3,711,000 after buying an additional 61,762 shares during the last quarter. Neuberger Berman Group LLC raised its position in shares of DexCom by 54.7% in the third quarter. Neuberger Berman Group LLC now owns 385,421 shares of the medical device company’s stock valued at $18,857,000 after buying an additional 136,205 shares during the last quarter. California Public Employees Retirement System increased its position in DexCom by 2.0% during the third quarter. California Public Employees Retirement System now owns 129,400 shares of the medical device company’s stock worth $6,331,000 after purchasing an additional 2,500 shares during the last quarter. Sessa Capital IM L.P. acquired a new position in DexCom during the third quarter worth approximately $14,678,000. Finally, Zions Bancorporation increased its position in DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares during the last quarter.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.